OphthaFund
Venture capitalCharleston · Pre-Seed–Series A
Investment thesis
The firm leverages deep expertise in ophthalmology and biotechnology to invest in specialized companies within these sectors. The team provides value-add support through drug development knowledge and access to a network of investors, partners, and subject matter experts.
Source: firm website, verified Aug 7, 2026.
What they invest in
from 5 of 12 portfolio companiesBiotech ×5Medical Devices ×3Healthtech ×2
HQs:United States×4Switzerland×1
Investments · 12 tracked
founders shown can be your intro pathPartnerTom Mather· solo GP
PartnerTom Mather· solo GP
PartnerTom Mather· solo GP
Co-investors2050atai Life SciencesAtaiBeckleyBlackbird GiantsCaduceus Capital PartnersFred Hutchinson Cancer Research Center+1 more
BiotechNew York, US
Geno Germano(Chief Executive Officer)Michael T. Smith(Director)Tim Boris(Director)Robert A. Ruffolo(Director)Teresa M. Ressel(Director)Ulrich Wiesner(Director)
PartnerTom Mather· solo GP
PartnerTom Mather· solo GP
ForwardVue Pharma develops a long-acting ORAI1 blocker administered by intravitreal injection to treat retinal neovascular disease, with a target dosing of 1-2 injections per year for durability up to 12 months.
BiotechHealthtechMedical DevicesMobile, US
Alan Franklin(Ophthalmologist, Vitreoretinal Diseases and Surgery)RAJ MATURI(Director)ALAN FRANKLIN(Executive Officer, Director)NEIL DONNENFELD(Director)RUBEN TIMMONS(Director)BARRY BUTLER(Director)
PartnerTom Mather· solo GP
PartnerTom Mather· solo GP
Biotechnology company developing treatments for ophthalmic diseases, focusing on dry eye through a topical ophthalmology platform.
BiotechSan Francisco, US
Tom Gadek(Founder)inThomas Gadek(Executive Officer, Director)Christopher J. Murphy(Director)Charles O'Neill(Executive Officer, Director)Tanya Shnaydman(Executive Officer)
PartnerTom Mather· solo GP
PartnerTom Mather· solo GP
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Co-Founder & Chief Scientific Officer)David Esposito(Executive Officer, Director)Constance Chang(Executive Officer)John K Freshley(Executive Officer, Director)Jeffrey A Jamison(Executive Officer)David N Zacks(Executive Officer, Director)
PartnerTom Mather· solo GP
Co-investorsExSight VenturesInvest MichiganNovartis Venture FundVisionary VenturesBios PartnersInFocus Capital Partners, LLC+3 more
Premark Pharma develops ophthalmic formulations of pimecrolimus, a topical anti-inflammatory compound, to treat blepharitis, dry eye, and ocular surface inflammation.
BiotechMedical Devices
PartnerTom Mather· solo GP
Frequently asked questions
- How many investments has OphthaFund made?
- OphthaFund has 12 tracked investments.
- What stage does OphthaFund invest at?
- OphthaFund invests at the Pre-Seed, Seed, Series A stages.
- What sectors does OphthaFund focus on?
- OphthaFund focuses on Biotech, Healthtech, Medical Devices.
- Where is OphthaFund located?
- OphthaFund is headquartered in Charleston, US.
- Does OphthaFund lead rounds?
- Yes, OphthaFund leads investment rounds.
- Who does OphthaFund co-invest with?
- OphthaFund most often shares deals with Caduceus Capital Partners, Michigan Capital Network, Novartis Venture Fund, among 13 tracked co-investors.
Images
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Arboretum Ventures is a Midwest-based healthcare venture capital firm that invests in early-stage healthcare startups across medical devices, life science tools and diagnostics, tech-enabled care delivery, and pharma adjacencies.